2015 Fiscal Year Final Research Report
Gene therapy for epilepsy by intravascular administration of Adeno-associated virus
Project/Area Number |
25460501
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Experimental pathology
|
Research Institution | Jichi Medical University |
Principal Investigator |
OGURO KEIJI 自治医科大学, 医学部, 准教授 (90231232)
|
Co-Investigator(Kenkyū-buntansha) |
SHIMAZAKI Kuniko 自治医科大学, 脳神経外科, 非常勤講師 (40142153)
YOKOTA Hidenori 自治医科大学, 脳神経外科, 講師 (90254929)
|
Co-Investigator(Renkei-kenkyūsha) |
MURAMATSU Shinichi 自治医科大学, 神経内科, 教授 (10239543)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Keywords | てんかん / 遺伝子治療 / ELマウス |
Outline of Final Research Achievements |
The purpose of this project is to develop a new therapy for the intractable epilepsy patients resistant to the conventional therapies including medication and surgery. We developed a new gene therapy using Adeno Associated Virus (AAV) vector pass through the blood brain barrier (BBB) which enables us to intravascular administration. We performed intracardiac injection of AAV-Neuroligin2 on epileptic EL mice. Neuroligin2 is a synapse related molecule which is known to induce or accelerate the formation of GABAergic synapses. We found that administrated AAV-Neuroligin2 is expressed over the brain including cortex and hippocampus and successfully suppress the seizure.
|
Free Research Field |
脳神経外科
|